Can-Fite BioPharma American Depositary Shares
CANF
14 hedge funds and large institutions have $429K invested in Can-Fite BioPharma American Depositary Shares in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
58% more capital invested
Capital invested by funds: $271K → $429K (+$157K)
3.07% more ownership
Funds ownership: 3.49% → 6.57% (+3.1%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less funds holding
Funds holding: 15 → 14 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$176K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$141K |
| 3 |
HF
HRT Financial
New York
|
+$80.1K |
| 4 |
VF
Virtu Financial
New York
|
+$53.4K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$28.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$193K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.58K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$3.74K |
| 4 |
BWL
Bogart Wealth LLC
Mclean,
Virginia
|
-$3.01K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$2.42K |
CANF Hedge Fund Activity: Q1 2026 in Review
14 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2026, worth a combined $429K — up 58% from $271K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CANF and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $176K. The largest seller was Jane Street, exiting entirely with an estimated $193K sold.
- 14 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2026, down from 15 in Q4 2025.
- Funds reported $429K of Can-Fite BioPharma American Depositary Shares stock for Q1 2026, up 58% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2026 and 6 closed out, a net change of -1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2026 was Sabby Management, an estimated $176K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2026 was Jane Street, an estimated $193K sold.
Based on aggregated 13F filings for Q1 2026.